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BACKGROUND Valve-in-valve TAVI (ViV-TAVI) has emerged as a
promising modality for high-risk patients with degenerated aortic
bioprostheses in order to avoid a new surgery, notwithstanding there
is still scarce data in literature supporting its use.
METHODS The Brazilian registry is a national real-world study that
enrolls patients treated with TAVI. ViV-TAVI patients from the regis-
try were analyzed and compared with the cohort of native valve pa-
tients. One-year all-cause mortality, stroke, NYHA functional class
were compared between groups.
RESULTS A total of 819 patients were included in the Brazilian TAVI
Registry. Among them, 34 patients underwent ViV-TAVI (64,7% Cor-
eValve, 35,3% Ballon expandable [BE] - Sapien XT/Inovare) for failed
surgical bioprosthetic valve and 785 make up the cohort of native
valve patients (73,2% CoreValve, 26,8% BE). ViV-TAVI patients were
younger (p<0.001), more symptomatic (p¼0.05), had more previous
CABG (p<0.001) and stroke (p¼0.045), and showed higher logistic
EuroSCORE (p¼0.003) than the native valve cohort. All-cause mor-
tality at 1-year was not different between groups (23.3% vs 21.6%,
p¼0.6), neither was the incidence of stroke (6.2% vs 7.2%, p¼0.8).
After 1 year ViV-TAVI patients were more symptomatic (NYHA Class I-
II: 80% vs 92.7%, p¼0.02).
CONCLUSIONS In this real-world registry, although ViV-TAVI pa-
tients were of higher risk, the procedure was not associated with
higher mortality or higher incidence of stroke at 1-year in comparison
with native valve TAVI. Nonetheless, the ViV-TAVI group remained
more symptomatic.
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BACKGROUND Although TAVI has proven to be safe and effective for
the treatment of aortic stenosis in high-risk patients, Balloon Aortic
Valvuloplasty (BAV) has not completely disappeared. On the contrary,
it’s sometimes indicated as a “bridge” to TAVI, that may eventually be
performed after clinical recovery. We present here the clinical and
economic outcomes of patients at prohibitive risk for surgery, treated
at our center with TAVI and/or BAV with this “bridging” intent.
METHODS Data of consecutive patients with severe aortic stenosis
treated at our center between 2010 and 2014 were collected and
analyzed retrospectively. Patients were classiﬁed based on the ther-
apeutic option (TAVI or BAV). Clinical events were collected by pa-
tients contact. For each patient costs were estimated for the initial
procedure and all subsequent hospitalizations.
RESULTS One-hundred and seven patients (84.9%) underwent TAVI
as a ﬁrst choice, while 19 patients (15.1%) received BAV. Subsequently,
7 of these patients (36.8%) had sufﬁcient clinical recovery and un-
derwent TAVI. Mean follow-up was 12.8 months in TAVI patients and
for 5.6 months in BAV patients. On average, TAVI patients were aged81 years, 73% were in NYHA class III/IV, and had a mean logistic
EuroSCORE of 27.9%. BAV treated patients were aged in mean 78
years, but had a higher proportion of NYHA class III/IV (95%) and were
at higher operative risk (Logistic EuroScore 37.3%). In-hospital mor-
tality was 2.8% for TAVI and 10.5% for BAV. Median length of hospital
stay was similar for both interventions: 9 days on general ward for
both, while 2 days and 1 day for TAVI and BAV patients, respectively,
were spent in ICU. At follow-up there were an average of 0.44 reho-
spitalizations per TAVI patient with mean length of stay of 14.3 days,
while BAV had 0.63 rehospitalizations per patient with an average
length of stay of 22.3 days. The index procedure costs were much
lower for BAV compared with TAVI (V9,222 vs V29,400). However,
observed follow-up costs at 12 months were V1,861 for TAVI against
V9,474 for BAV. Based on the projected survival curves at 1, 2 and 3
years, the incremental cost-effectiveness ratio, deﬁned as the differ-
ence in cost divided by the difference in life expectancy, was calcu-
lated. At 1 year the incremental cost-effectiveness ratio for TAVI vs
BAV was V61.500 per year of life gained, decreasing to V19.500 by the
second year. From the third year, TAVI was anticipated to be more
effective and less costly (“dominant” strategy) than BAV.
CONCLUSIONS Treatment of severe aortic stenosis with TAVI bears
excellent clinical outcomes. However, BAV may be chosen as desti-
nation or “bridge” therapy in a limited group of patients at higher risk
that may eventually recover and become TAVI candidates. TAVI
seems overall a more effective clinical option, and when considering
time periods beyond 1 year may be cost-effective and even cost saving
compared to BAV. Larger and more homogeneous samples may be of
help in further clarifying this topic.
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BACKGROUND In the transcatheter aortic valve implantation (TAVI)
era, there is a renewed impulse to perform percutaneous balloon
aortic valvuloplasty (BAV). Aside its high percentage of procedural
success and consequent potential symptoms relief, BAV is still asso-
ciated with possible harm in frail patients such those with degenera-
tive aortic valve stenosis (AS). We sought to evaluate the incidence of
acute aortic regurgitation (ARR) complicating BAV and analyze the
treatment options and in -hospital outcome.
METHODS From the prospective BAV registry of the University of
Bologna, which has enrolled patients between the year 2000 and the
present, we selected those suffering intraprocedural AAR with overt
hemodynamic instability. Worsening of baseline aortic insufﬁciency
without hemodynamic collapse, treatment of biological valve pros-
thesis and BAV occurring within a transcatheter aortic valve implan-
tation (TAVI) procedure were reasons of exclusion.
RESULTS Over 15 years, of 1517 BAV we identiﬁed 26 cases of AAR and
so an incidence of 1.7%. The complication happened in about 80% of
cases after one or two balloon inﬂations. Mean trans-aortic gradient
decreased from 50.619.3 mmHg to 26.014.4 mmHg (p<0.01),
whereas the average systolic and diastolic pressure collected did not
differed from baseline to post BAV. In 8(30.8%) patients AAR spon-
taneously resolved, but in 13(50.0%) the operator had to perform a
rescue maneuver to reposition a valve leaﬂet got stuck in the opening
position: a pig-tail catheter with a J or extra-stiff wire inside was
pushed towards the leaﬂet and turned gently clockwise and coun-
terclockwise. Emergency TAVI or surgery let to treat 3 cases. In-hos-
pital mortality was 15.4% (n¼4).
CONCLUSIONS AAR is still a fearsome complication of BAV both in
term of incidence and grim prognosis. However the operators should
be aware of the possibility to treat it in the cath lab with proper
technical maneuvers in a high percentage of cases. TAVI or surgical
valve replacement are alternative options.
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